{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-166855","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.880788+00:00","generated_at":"2026-06-14T01:06:51.773386+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Agios stockholders approve 2023 Stock Incentive Plan; elect three Class I directors","bullets":["Elected Rahul Ballal, Brian Goff, and Cynthia Smith as Class I directors for terms expiring at the 2026 annual meeting.","2023 Stock Incentive Plan approved with 27,268,226 votes for, 23,635,666 against, and 25,531 abstentions.","Non-binding advisory vote on named executive officer compensation passed (46,289,192 for, 4,630,627 against).","PricewaterhouseCoopers LLP ratified as independent auditor for fiscal 2023 (50,024,364 for, 1,876,012 against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-166855","json":"https://secwatch.observer/filing/0001193125-23-166855.json","markdown":"https://secwatch.observer/filing/0001193125-23-166855.md","text":"https://secwatch.observer/filing/0001193125-23-166855.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523166855/0001193125-23-166855-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523166855/d415331d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:06:51.773386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56ebbf81e1b52d2ab71a48f1a42b9dded3bd210f","claim":"AGIOS PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-04-26 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the current fiscal year.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523166855/0001193125-23-166855-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-26"}],"fact_type":"shareholder_vote"},{"claim_id":"7e5a91cfab93b99e77fb1c1b1fbb0f3e171a15a5","claim":"AGIOS PHARMACEUTICALS, INC. shareholders approved Approval of the 2023 Plan at the 2023-04-26 meeting.","evidence_excerpt":"The Company’s stockholders approved the 2023 Plan.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523166855/0001193125-23-166855-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-26"}],"fact_type":"shareholder_vote"},{"claim_id":"95a5a7b3efb62f1238d900596cdfadfe1d3ef6e3","claim":"AGIOS PHARMACEUTICALS, INC. shareholders approved Election of Class I directors at the 2023-04-26 meeting.","evidence_excerpt":"The Company’s stockholders elected Rahul Ballal, Brian Goff and Cynthia Smith as Class I directors, each to serve for a three-year term expiring at the 2026 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523166855/0001193125-23-166855-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-26"}],"fact_type":"shareholder_vote"},{"claim_id":"fb8bff6d540c20c12bf5cc6e2d9059984540cb8e","claim":"AGIOS PHARMACEUTICALS, INC. shareholders approved Non-binding advisory vote on compensation paid to named executive officers at the 2023-04-26 meeting.","evidence_excerpt":"The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523166855/0001193125-23-166855-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-26"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}